Phase 2 trial of the IDO pathway inhibitor indoximod plus gemcitabine / nab-paclitaxel for the treatment of patients with metastatic pancreas cancer.

4015Background: The indoleamine 2,3-dioxygenase (IDO) pathway is a key counter-regulatory mechanism that is exploited by tumors to prevent and evade anti-tumor immunity. Inhibitors of the IDO pathw...